10 completed, 3 terminated, 2 active not recruiting. 13 Phase 1, 2 Phase 2.
By phase and status
Follow Aligos Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function Pevifoscorvir Sodium (ALG-000184) - Chronic Hepatitis B Infection Phase 1 Completed 12 2026-03-10 2026-08-21 Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function Pevifoscorvir Sodium (ALG-000184) - Chronic Hepatitis B Infections Phase 1 Completed 20 2026-01-30 2026-08-21 A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME) ALG-000184, TDF - Chronic Hepatitis B Infection Phase 2 Active not recruiting 200 2025-07-15 2026-09-11 A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations ALG-055009 - Healthy Volunteer Study Phase 1 Completed 8 2025-03-25 2025-07-09 A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Renal Impairment and in Healthy Subjects With Normal Renal Function ALG-097558 - COVID 19 Phase 1 Completed 12 2025-02-20 2026-08-25 A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function ALG-097558 - COVID-19 Phase 1 Completed 16 2025-01-13 2026-08-05 A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy Volunteers Carbamazepine, Itraconazole (Sporanox), ALG-000184 - Healthy Volunteer Phase 1 Active not recruiting 24 2025-01-09 2025-02-03 ALG-055009 in Non-cirrhotic Adults With MASH (HERALD) ALG-055009, Placebo - NASH, MASH Phase 2 Completed 102 2024-04-01 2025-02-17 A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies) Atorvastatin, ALG-055009, Rosuvastatin - Healthy Volunteers Phase 1 Completed 14 2023-11-03 2025-02-17 A First-in-Human Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interaction Potential of Single and Multiple Doses of ALG-097558 ALG-097558, Placebo, Midazolam - COVID-19 Phase 1 Completed 90 2023-07-04 2025-04-08 A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB Subjects ALG-125755, Placebo - Chronic Hepatitis B Phase 1 Terminated 57 2022-10-07 2024-03-15 A Study of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia ALG-055009, Placebo - NASH - Nonalcoholic Steatohepatitis Phase 1 Completed 98 2021-12-01 2023-09-25 A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects ALG-020572, Placebo - Chronic Hepatitis B Phase 1 Terminated 40 2021-09-25 2023-04-25 A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects ALG-000184, Placebo, Entecavir - Chronic Hepatitis B Phase 1 Completed 165 2020-10-22 2025-11-21 A Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects ALG-010133, Placebo - Chronic Hepatitis B Phase 1 Terminated 103 2020-08-17 2022-03-15
Conditions studied Hepatitis B, Chronic (6) · COVID-19 (3) · Non-alcoholic Fatty Liver Disease (2) · Hepatitis B (1) · Liver Diseases (1)
Interventions Carbamazepine (2) · Itraconazole (2) · Atorvastatin (1) · Midazolam (1) · Rosuvastatin Calcium (1) · entecavir (1)
Countries United States (9) · New Zealand (5) · Moldova (4) · United Kingdom (4) · China (3) · Hong Kong (3) · Bulgaria (2) · France (2) · Romania (2) · South Korea (2) · Australia (1) · Canada (1) · Italy (1) · Mauritius (1) · Spain (1)
Top investigators Stephen Harrison, MD (1)
Results publications PMID 34280012 , PMID 41268712 , PMID 41554267 , PMID 42648297